To elucidate the role of mutation(s) in BORIS gene in the progression of breast cancer revealed a significant association of BORIS mutation and patients’ clinical stage (p = 0.010), nodal status (p = 0.013), ER (p = 0.008), PR (p = 0.039) expression and menopausal status (p = 0.023) (Table 1). This evidence concerns the gene CTCFL and breast cancer.